Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a San Diego-based clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of novel therapeutics in the areas of immunology, inflammation, and oncology. Founded by the former executive team of Receptos, Gossamer Bio leverages a rich asset in-licensing environment with a focus on addressing high unmet medical needs.
The company's core strategy revolves around utilizing a team with a proven track record in key therapeutic areas such as immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising products:
- Seralutinib: Aimed at treating pulmonary arterial hypertension (PAH) by addressing cellular overgrowth, fibrosis, and vascular remodeling.
- GB004: Focused on treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
- GB1275: Targeting various oncology indications with innovative treatment strategies.
- GB001: Designed for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio's approach combines cutting-edge science with a commitment to improving patient outcomes. The company continuously works on expanding its pipeline through strategic partnerships and collaborations, ensuring a robust portfolio of therapeutic candidates.
Recent achievements include advancements in clinical trials for Seralutinib and GB004, showcasing the company's potential to deliver impactful treatments. Gossamer Bio remains focused on executing its mission to bring differentiated therapeutic solutions to patients with significant unmet needs.
For investors and stakeholders, Gossamer Bio represents a dynamic and innovative player in the biopharmaceutical space, committed to scientific excellence and patient-centric solutions.
Gossamer Bio reported its financial results for Q4 and full year 2022, highlighting a net loss of $55.8 million or $0.59 per share in Q4, and a full-year net loss of $229.4 million or $2.71 per share. Cash, cash equivalents, and marketable securities were $256 million, expected to sustain operations into the second half of 2024. The company plans to initiate a Phase 3 clinical trial for Seralutinib (GB002) in pulmonary arterial hypertension in H2 2023, while enrollment in the Phase 1b/2 GB5121 CNS study is paused.
Gossamer Bio announced promising topline results from the TORREY Phase 2 study of seralutinib in treating pulmonary arterial hypertension (PAH). The primary endpoint, change in pulmonary vascular resistance (PVR) at Week 24, was met with a statistically significant P-value of 0.0310. Secondary endpoints also favored seralutinib, particularly in patients classified as WHO Functional Class III, showing a 21% reduction in PVR and a 37-meter improvement in six-minute walk distance (6MWD). Seralutinib exhibited a favorable safety profile, with most adverse events being mild to moderate.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio, Inc.?
Where is Gossamer Bio, Inc. located?
What are the main areas of focus for Gossamer Bio's therapeutic products?
Who founded Gossamer Bio, Inc.?
What is Seralutinib used for?
What conditions does GB004 target?
What is GB1275 used to treat?
What stage is Gossamer Bio at in its development?
How does Gossamer Bio expand its pipeline?
What is GB001 designed for?
